Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.
Wenn das Problem der Verringerung der Potenz berührt mich persönlich war ich schockiert, dass das passiert gerade mit mir kamagra Übrigens jeder leisten und gibt eine sofortige Wirkung ohne Hausarbeiten Anwendungen.
Prog complet
26–29 June • World Trade & Convention Centre
COS and Affiliated Societies
Annual Meeting & Exhibition 2003
Scientific Program
Day 2 / Jour 2 Friday, June 27 / Vendredi 27 juin
Canadian Retina and Vitreous Society /
Société canadienne de la rétine et du vitré
Objectives: The presentations are largely of a clinical research nature. The participants will have the opportu-
nity to review and discuss novel medical and surgical techniques and applications to help determine when and
how they might be included in their clinical practice.
Objectifs : L’exposé consiste surtout en une recherche clinique. Les participants auront l’occasion de revoir les
nouvelles techniques et applications médicales et chirurgicales et d’examiner ensemble quand et comment ils
pourraient les inclure dans leur pratique clinique.
Guest / Invitée :Johanna M. Seddon, Boston, Massachusetts
Medical Retina I / Soins thérapeutiques
de la rétine I
Session chair / Présidence :
Arif Samad
1030
Clinical–biochemical correlations in Oguchi’s disease
1050
Discussion
1100
Abstract A-1
Mutant frizzled-4 (FZD4) causes autosomal dominant familial exudative vitreoretinopathy with vari-
able intrafamilial phenotype
J. Robitaille,* M.L.E. MacDonald,
A. Kaykas, L. Sheldahl, M.-P. Dube,
D.L. Guernsey, B. Zheng, L.S. Siebert,
A. Hoskin-Mott, M.J. Beis, S.N. Pimstone, B.S. Shastry, R.T. Moon, M.R. Hayden,
Y.P. Goldberg, M.E. Samuels
1107
Abstract A-2
The effect of docosahexaenoic acid supplementation on macular function in a patient with a muta-
tion in ELOVL4
I.M. MacDonald,* M. Hébert, R.J. Yau,
S. Flynn, J. Jumpsen, M. Suh,
M.T. Clandinin
1114
Abstract A-3
Changes in multifocal electroretinography amplitude, but not timing, secondary to chloroquine and
hydroxychloroquine toxicity
A. Bhargava,* S.G. Coupland, P.J. Kertes, B.C. Leonard
1121
Discussion
1130
Abstract A-4
Five-year outcomes of the Canadian proton radiation therapy experience K.E. Paton, L.A. Wittenberg*
1137
Abstract A-5
Neovascular glaucoma following proton beam radiation therapy: risk factors, monitoring and treat-
ment strategies
K.E. Paton,* L.A. Wittenberg
1144
Abstract A-6
Bilateral exudative retinal detachment as initial presentation of sympathetic ophthalmia
C.W. Chang,* M.D.J. Greve, B.J. Hinz
1151
Discussion
1200–1330
Lunch / Déjeuner
Surgical Retina / Soins chirurgicaux de la rétine
Session chair / Présidence :Peter J. Kertes
1330
Retinal detachment in developing countries
1350
Discussion
1400
Abstract A-7
Posterior vitreous detachment: Is the 6-week follow-up necessary?
First prize, COS/Coherent-AMT Award for Excellence in Ophthalmic Research / Premier prix d’excel-
lence SCO/Coherent-AMT en recherche ophtalmique
K. Hasanee,* S. Sharma
1407
Abstract A-8
The new 25-gauge sutureless vitrectomy: outcomes and complications
M.-J. Fredette,* Y. Tardif, B. Cinq-Mars
1414
Abstract A-9
Massive peripapillary choroidal neovascularization: an indication for submacular surgery
P.J. Kertes
1421
Discussion
1430
Abstract A-10
Visual outcome of epiretinal membrane surgery with trypan blue
M. Perrier,* M. Sébag
1437
Abstract A-11
Outcome of macular hole surgery using trypan blue to facilitate delamination of the internal limiting
membrane
M. Perrier,* M. Sébag
1444
The etiology of macular detachment in an optic nerve pit/coloboma
1451
Discussion
1500–1530
Break / Pause
Medical Retina II / Soins thérapeutiques de la rétine II
Session chair / Présidence :Murray J. Erasmus
1550
Discussion
1600
Abstract A-12
Can multifocal electroretinography be used to follow patients with age-related macular degeneration
after photodynamic therapy and predict the need for retreatment?
M.-J. Fredette,* H. Shekavat, G. Lalonde, B. Cinq-Mars, Y. Tardif, M. Malenfant,
M. Hébert
1607
Abstract A-13
Does photodynamic therapy retreatment affect electroretinal function?
S.G. Coupland,* B.C. Leonard, P.J. Kertes
1614
Abstract A-14
Off-label uses of photodynamic therapy
R. Varma,* M.J. Erasmus, K. Colleaux
1621
Discussion
1630
Abstract A-15
Evaluation of active and clinically resolved central serous chorioretinopathy with multifocal elec-
troretinography
L.A. Wittenberg,* D. Maberley
1637
Abstract A-16
Micropulsed diode laser treatment for chronic idiopathic central serous chorioretinopathy
F. Ali,* N. Armogan, J. Freudenthal
1644
Abstract A-17
Focal laser treatment of retinal angiomatous proliferations guided by high-speed indocyanine green
imaging
T.M. Johnson,* B.M. Glaser
1651
Discussion
Source: http://www.cos-sco.ca/annualmeeting/halifax2003/program/pdf-programs/05-crvs.pdf
Risk communication: Why we need Not involving patients in important medical decisions is also understandable information ethically unjustifiable, as it is their health that is at stake. It is premature to give up on people’s ability toThis is particularly important as patients and physicians dounderstand health statistics. The example of the pill scarenot always have the same pre
Human Resources Center425 Pennsylvania Avenue Ground Covers Landscape considerations. Present day landscape If the area to be covered is large, it is generally design stresses simplicity. Often a few widely advisable to develop a broad, mass planting using spaced, carefully selected specimen plants are used one kind of plant. Occasionally, two or three kinds to create an interesting